Specialists in neuroimaging at UB have proposed a mechanism by which interferon beta-1a may limit brain atrophy in multiple sclerosis (MS) patients. The positive effect of interferon beta-1a, a ...
Please provide your email address to receive an email when new articles are posted on . Researchers compared data from those treated in the phase 3 EVOLVE-MS-1 and DECIDE studies. Treatment with ...
NEW YORK (Reuters Health) - Early treatment of multiple sclerosis (MS) patients with interferon beta-1b therapy may help slow down the onset of disability, according to a report in this week's issue ...
Patients with clinically isolated syndromes (CIS) are prone to develop multiple sclerosis (MS). The randomized, placebo-controlled CHAMPS trial found early treatment with interferon -1a to be ...
In RRMS, the early course of the disease is characterised by intermittent relapses, and partial or complete recovery of function between exacerbations. The occurrence of relapses is a key measure of ...
medwireNews: The DECIDE study shows that 4-weekly daclizumab high-yield process (HYP) reduces disease activity in patients with relapsing–remitting multiple sclerosis (MS) more effectively than weekly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback